{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:56:07Z","timestamp":1791834967984,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Studies from various countries raise concerns on the association between dopamine agonist (DA) treatment and impulse control disorders (ICDs) in patients with pituitary adenomas. We investigated the prevalence of ICDs in patients with pituitary adenomas in a UK centre using two instruments applied in clinical practice for assessing ICDs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cross-sectional study of adults with prolactinoma, acromegaly or non-functioning pituitary adenoma (NFPA) treated or not with DAs in a pituitary centre. Screening tools for ICD were the Minnesota Impulse Disorders Interview (MIDI) and Questionnaire for Impulsive-Compulsive Disorders in Parkinson\u2019s Disease Rating Scale (QUIP-RS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Data from 200 patients were analysed [72 prolactinomas (on DA), 71 NFPAs (no DA), 57 with acromegaly (12 on DA)]. The percentage of patients scoring for any ICD was higher in the prolactinoma on DA group compared with the NFPA cases; MIDI 12.7% vs. 1.4% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02) and QUIP-RS 46.5% vs. 18.6% (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), respectively. DA use was associated with positive scores for all ICDs in the MIDI and with compulsive buying and hobbyism-punding in the QUIP-RS. DA dose or treatment duration were not associated with positive scores. The responses of patients with acromegaly on DA did not differ from those not on these agents in any questionnaire.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this sample of UK patients, prevalence of ICDs is higher in prolactinoma patients on DA compared to those with NFPA not on DA. Differences were not observed between patients with acromegaly treated or not with DA. Different ICD assessment tools have an impact on the detected outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11102-025-01517-0","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T08:44:42Z","timestamp":1745225082000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Impulse control disorders in patients with pituitary adenoma managed with or without dopamine agonists: a cross-sectional study from a UK centre"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9801-0458","authenticated-orcid":false,"given":"Ross","family":"Hamblin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9467-3411","authenticated-orcid":false,"given":"Athanasios","family":"Fountas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4696-0643","authenticated-orcid":false,"given":"Niki","family":"Karavitaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"issue":"8","key":"1517_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s00406-006-0668-0","volume":"256","author":"B Dell\u2019Osso","year":"2006","unstructured":"Dell\u2019Osso B, Altamura AC, Allen A, Marazziti D, Hollander E (2006) Epidemiologic and clinical updates on impulse control disorders: a critical review. Eur Arch Psychiatry Clin NeuroSci 256(8):464\u2013475. https:\/\/doi.org\/10.1007\/s00406-006-0668-0","journal-title":"Eur Arch Psychiatry Clin NeuroSci"},{"key":"1517_CR2","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association D, American Psychiatric Association D (2013) Diagnostic and statistical manual of mental disorders: DSM-5. American psychiatric association Washington, DC","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"1","key":"1517_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1176\/appi.ajp.2018.18040465","volume":"176","author":"D Weintraub","year":"2019","unstructured":"Weintraub D, Mamikonyan E (2019) Impulse control disorders in Parkinson\u2019s disease. Am J Psychiatry 176(1):5\u201311. https:\/\/doi.org\/10.1176\/appi.ajp.2018.18040465","journal-title":"Am J Psychiatry"},{"issue":"6","key":"1517_CR4","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/cen.12375","volume":"80","author":"I Bancos","year":"2014","unstructured":"Bancos I, Nannenga MR, Bostwick JM, Silber MH, Erickson D, Nippoldt TB (2014) Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol (Oxf) 80(6):863\u2013868. https:\/\/doi.org\/10.1111\/cen.12375","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"1517_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s11102-013-0480-6","volume":"17","author":"M Barake","year":"2014","unstructured":"Barake M, Evins AE, Stoeckel L et al (2014) Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. Pituitary 17(2):150\u2013156. https:\/\/doi.org\/10.1007\/s11102-013-0480-6","journal-title":"Pituitary"},{"issue":"8","key":"1517_CR6","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s40618-020-01478-0","volume":"44","author":"G Beccuti","year":"2021","unstructured":"Beccuti G, Guaraldi F, Natta G et al (2021) Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study. J Endocrinol Invest 44(8):1699\u20131706. https:\/\/doi.org\/10.1007\/s40618-020-01478-0","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"1517_CR7","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s12020-018-1744-8","volume":"62","author":"E Celik","year":"2018","unstructured":"Celik E, Ozkaya HM, Poyraz BC, Saglam T, Kadioglu P (2018) Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up. Endocrine 62(3):692\u2013700. https:\/\/doi.org\/10.1007\/s12020-018-1744-8","journal-title":"Endocrine"},{"key":"1517_CR8","doi-asserted-by":"publisher","unstructured":"De Sousa SMC, Baranoff J, Rushworth RL et al (2020) Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors. J Clin Endocrinol Metab 105(3). https:\/\/doi.org\/10.1210\/clinem\/dgz076","DOI":"10.1210\/clinem\/dgz076"},{"issue":"7","key":"1517_CR9","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1210\/jc.2018-02202","volume":"104","author":"SC Dogansen","year":"2019","unstructured":"Dogansen SC, Cikrikcili U, Oruk G et al (2019) Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study. J Clin Endocrinol Metab 104(7):2527\u20132534. https:\/\/doi.org\/10.1210\/jc.2018-02202","journal-title":"J Clin Endocrinol Metab"},{"key":"1517_CR10","doi-asserted-by":"publisher","first-page":"579606","DOI":"10.3389\/fendo.2020.579606","volume":"11","author":"JM Hinojosa-Amaya","year":"2020","unstructured":"Hinojosa-Amaya JM, Johnson N, Gonzalez-Torres C et al (2020) Depression and impulsivity self-assessment tools to identify dopamine agonist side effects in patients with pituitary adenomas. Front Endocrinol (Lausanne) 11:579606. https:\/\/doi.org\/10.3389\/fendo.2020.579606","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1517_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12902-022-01009-3","volume":"22","author":"X Ke","year":"2022","unstructured":"Ke X, Wang L, Chen M et al (2022) The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study. BMC Endocr Disord 22(1):97. https:\/\/doi.org\/10.1186\/s12902-022-01009-3","journal-title":"BMC Endocr Disord"},{"key":"1517_CR12","doi-asserted-by":"crossref","unstructured":"Ozdeniz Varan E, Gurvit H (2022) Effect of dopaminergic therapy on impulse control disorders in patients with a prolactinoma. Cogn Behav Neurol 26","DOI":"10.1097\/WNN.0000000000000320"},{"key":"1517_CR13","doi-asserted-by":"publisher","first-page":"101356","DOI":"10.1016\/j.ghir.2020.101356","volume":"55","author":"HM Ozkaya","year":"2020","unstructured":"Ozkaya HM, Sahin S, Korkmaz OP et al (2020) Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas. Growth Horm IGF Res 55:101356. https:\/\/doi.org\/10.1016\/j.ghir.2020.101356","journal-title":"Growth Horm IGF Res"},{"issue":"5","key":"1517_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/WNF.0b013e3182281b2f","volume":"34","author":"J Martinkova","year":"2011","unstructured":"Martinkova J, Trejbalova L, Sasikova M, Benetin J, Valkovic P (2011) Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clin Neuropharmacol 34(5):179\u2013181. https:\/\/doi.org\/10.1097\/WNF.0b013e3182281b2f","journal-title":"Clin Neuropharmacol"},{"issue":"8","key":"1517_CR15","doi-asserted-by":"publisher","first-page":"102910","DOI":"10.1016\/j.arcmed.2023.102910","volume":"54","author":"R Hamblin","year":"2023","unstructured":"Hamblin R, Karavitaki N (2023) Impulse control disorders in patients with pituitary tumors treated with dopamine agonists: a systematic review. Arch Med Res 54(8):102910. https:\/\/doi.org\/10.1016\/j.arcmed.2023.102910","journal-title":"Arch Med Res"},{"issue":"4","key":"1517_CR16","doi-asserted-by":"publisher","first-page":"e58516","DOI":"10.7759\/cureus.58516","volume":"16","author":"MM Mohammad","year":"2024","unstructured":"Mohammad MM, Alidrisi HA, Mansour AA (2024) Impulse control disorders in Southern Iraqi patients medicated with cabergoline for prolactinoma. Cureus 16(4):e58516. https:\/\/doi.org\/10.7759\/cureus.58516","journal-title":"Cureus"},{"issue":"2","key":"1517_CR17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11102-024-01383-2","volume":"27","author":"MH Almalki","year":"2024","unstructured":"Almalki MH, Alsuraikh MA, Almalki E et al (2024) Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study. Pituitary 27(2):197\u2013203. https:\/\/doi.org\/10.1007\/s11102-024-01383-2","journal-title":"Pituitary"},{"issue":"4","key":"1517_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11102-023-01342-3","volume":"26","author":"C Sulu","year":"2023","unstructured":"Sulu C, Gul N, Tanrikulu S et al (2023) Risk of impulse control disorders in patients with Cushing\u2019s disease: do not blame cabergoline but do not give up caution. Pituitary 26(4):495\u2013509. https:\/\/doi.org\/10.1007\/s11102-023-01342-3","journal-title":"Pituitary"},{"issue":"12","key":"1517_CR19","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement. Nat Reviews Endocrinol 19(12):722\u2013740. https:\/\/doi.org\/10.1038\/s41574-023-00886-5","journal-title":"Nat Reviews Endocrinol"},{"issue":"1","key":"1517_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11102-023-01365-w","volume":"27","author":"I Ayalon-Dangur","year":"2024","unstructured":"Ayalon-Dangur I, Turjeman A, Hirsch D et al (2024) Cabergoline treatment for surgery-na\u00efve non-functioning pituitary macroadenomas. Pituitary 27(1):52\u201360. https:\/\/doi.org\/10.1007\/s11102-023-01365-w","journal-title":"Pituitary"},{"issue":"7","key":"1517_CR21","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s40618-021-01661-x","volume":"45","author":"R Pivonello","year":"2022","unstructured":"Pivonello R, Pivonello C, Simeoli C, De Martino MC, Colao A (2022) The dopaminergic control of Cushing\u2019s syndrome. J Endocrinol Invest 45(7):1297\u20131315. https:\/\/doi.org\/10.1007\/s40618-021-01661-x","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"1517_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12020-015-0727-2","volume":"51","author":"S Noronha","year":"2016","unstructured":"Noronha S, Stokes V, Karavitaki N, Grossman A (2016) Treating prolactinomas with dopamine agonists: always worth the gamble? Endocrine 51(2):205\u2013210. https:\/\/doi.org\/10.1007\/s12020-015-0727-2","journal-title":"Endocrine"},{"issue":"2","key":"1517_CR23","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s12020-016-1088-1","volume":"55","author":"SM De Sousa","year":"2017","unstructured":"De Sousa SM, Chapman IM, Falhammar H, Torpy DJ (2017) Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists. Endocrine 55(2):618\u2013624. https:\/\/doi.org\/10.1007\/s12020-016-1088-1","journal-title":"Endocrine"},{"key":"1517_CR24","doi-asserted-by":"crossref","unstructured":"Correa e Castro AC, de Araujo AA, Botelho MC et al (2022) Binge eating and compulsive buying during cabergoline treatment for prolactinoma: a case report. Front Psychiatry 13 (no pagination).","DOI":"10.3389\/fpsyt.2022.844718"},{"issue":"4","key":"1517_CR25","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1176\/jnp.2007.19.4.473","volume":"19","author":"M Davie","year":"2007","unstructured":"Davie M (2007) Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. J Neuropsychiatry Clin Neurosci 19(4):473\u2013474. https:\/\/doi.org\/10.1176\/jnp.2007.19.4.473","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"1517_CR26","doi-asserted-by":"crossref","unstructured":"Falhammar H, Yarker JY (2009) Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. Med J Aust 190(2):97","DOI":"10.5694\/j.1326-5377.2009.tb02289.x"},{"issue":"5","key":"1517_CR27","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/s41574-024-00953-5","volume":"20","author":"ZB Wu","year":"2024","unstructured":"Wu ZB (2024) The shift of therapeutic strategy for prolactinomas: surgery as the first-line option. Nat Reviews Endocrinol 20(5):310\u2013310. https:\/\/doi.org\/10.1038\/s41574-024-00953-5","journal-title":"Nat Reviews Endocrinol"},{"issue":"5","key":"1517_CR28","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archneurol.2010.65","volume":"67","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Koester J, Potenza MN et al (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67(5):589\u2013595. https:\/\/doi.org\/10.1001\/archneurol.2010.65","journal-title":"Arch Neurol"},{"issue":"12","key":"1517_CR29","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1001\/jamainternmed.2014.5262","volume":"174","author":"TJ Moore","year":"2014","unstructured":"Moore TJ, Glenmullen J, Mattison DR (2014) Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 174(12):1930\u20131933. https:\/\/doi.org\/10.1001\/jamainternmed.2014.5262","journal-title":"JAMA Intern Med"},{"issue":"3","key":"1517_CR30","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1007\/s00415-021-10724-1","volume":"269","author":"L Cao","year":"2022","unstructured":"Cao L, Xu T, Zhao G, Lv D, Lu J, Zhao G (2022) Risk factors of impulsive-compulsive behaviors in PD patients: a meta-analysis. J Neurol 269(3):1298\u20131315. https:\/\/doi.org\/10.1007\/s00415-021-10724-1","journal-title":"J Neurol"},{"issue":"2","key":"1517_CR31","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1212\/WNL.0b013e31827b915c","volume":"80","author":"D Weintraub","year":"2013","unstructured":"Weintraub D, Papay K, Siderowf A, Parkinson\u2019s Progression Markers I (2013) Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology 80(2):176\u2013180. https:\/\/doi.org\/10.1212\/WNL.0b013e31827b915c","journal-title":"Neurology"},{"issue":"1","key":"1517_CR32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4103\/0028-3886.370452","volume":"71","author":"G Sanjan","year":"2023","unstructured":"Sanjan G, Das L, Ahuja CK et al (2023) Impulse control disorders with short-term use of cabergoline in macroprolactinomas: a prospective study with a brief review of literature. Neurol India 71(1):107\u2013112. https:\/\/doi.org\/10.4103\/0028-3886.370452","journal-title":"Neurol India"},{"issue":"6","key":"1517_CR33","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1210\/clinem\/dgac718","volume":"108","author":"S Sahin","year":"2023","unstructured":"Sahin S, Sudutan T, Kavla Y et al (2023) A genetic assessment of dopamine agonist-induced impulse control disorder in patients with prolactinoma. J Clin Endocrinol Metab 108(6):e275\u2013e282. https:\/\/doi.org\/10.1210\/clinem\/dgac718","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1517_CR34","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1530\/EJE-08-0896","volume":"160","author":"C Sievers","year":"2009","unstructured":"Sievers C, Ising M, Pfister H et al (2009) Personality in patients with pituitary adenomas is characterized by increased anxiety-related traits: comparison of 70 acromegalic patients with patients with non-functioning pituitary adenomas and age-and gender-matched controls. Eur J Endocrinol 160(3):367\u2013373","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1517_CR35","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000335996","volume":"96","author":"AP Athanasoulia","year":"2012","unstructured":"Athanasoulia AP, Ising M, Pfister H, Mantzoros CS, Stalla GK, Sievers C (2012) Distinct dopaminergic personality patterns in patients with prolactinomas: a comparison with nonfunctioning pituitary adenoma patients and age- and gender-matched controls. Neuroendocrinology 96(3):204\u2013211. https:\/\/doi.org\/10.1159\/000335996","journal-title":"Neuroendocrinology"},{"key":"1517_CR36","doi-asserted-by":"publisher","first-page":"101439","DOI":"10.1016\/j.ghir.2021.101439","volume":"62","author":"EK Kan","year":"2022","unstructured":"Kan EK, Atmaca A, Sarisoy G, Ecemis GC, Gokosmanoglu F (2022) Personality traits in acromegalic patients: comparison with patients with non-functioning adenomas and healthy controls. Growth Horm IGF Res 62:101439. https:\/\/doi.org\/10.1016\/j.ghir.2021.101439","journal-title":"Growth Horm IGF Res"},{"key":"1517_CR37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.psychres.2018.05.006","volume":"265","author":"SR Chamberlain","year":"2018","unstructured":"Chamberlain SR, Grant JE (2018) Minnesota impulse disorders interview (MIDI): validation of a structured diagnostic clinical interview for impulse control disorders in an enriched community sample. Psychiatry Res 265:279\u2013283. https:\/\/doi.org\/10.1016\/j.psychres.2018.05.006","journal-title":"Psychiatry Res"},{"issue":"11","key":"1517_CR38","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1176\/appi.ajp.162.11.2184","volume":"162","author":"JE Grant","year":"2005","unstructured":"Grant JE, Levine L, Kim D, Potenza MN (2005) Impulse control disorders in adult psychiatric inpatients. Am J Psychiatry 162(11):2184\u20132188. https:\/\/doi.org\/10.1176\/appi.ajp.162.11.2184","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1517_CR39","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/mds.24023","volume":"27","author":"D Weintraub","year":"2012","unstructured":"Weintraub D, Mamikonyan E, Papay K, Shea JA, Xie SX, Siderowf A (2012) Questionnaire for impulsive-compulsive disorders in Parkinson\u2019s disease-rating scale. Mov Disord 27(2):242\u2013247. https:\/\/doi.org\/10.1002\/mds.24023","journal-title":"Mov Disord"},{"issue":"3","key":"1517_CR40","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.parkreldis.2010.11.015","volume":"17","author":"K Papay","year":"2011","unstructured":"Papay K, Mamikonyan E, Siderowf AD et al (2011) Patient versus informant reporting of ICD symptoms in Parkinson\u2019s disease using the QUIP: validity and variability. Parkinsonism Relat Disord 17(3):153\u2013155. https:\/\/doi.org\/10.1016\/j.parkreldis.2010.11.015","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"1517_CR41","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/mds.27689","volume":"34","author":"AH Evans","year":"2019","unstructured":"Evans AH, Okai D, Weintraub D et al (2019) Scales to assess impulsive and compulsive behaviors in Parkinson\u2019s disease: critique and recommendations. Mov Disord 34(6):791\u2013798. https:\/\/doi.org\/10.1002\/mds.27689","journal-title":"Mov Disord"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01517-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-025-01517-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01517-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:20:26Z","timestamp":1751383226000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-025-01517-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1517"],"URL":"https:\/\/doi.org\/10.1007\/s11102-025-01517-0","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"15 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NK is a member of the Editorial Board of Pituitary. The authors have no other conflicts of interest to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}